Corcept Raises 2026 Revenue Guidance, Targets Significant Sales Growth

Corcept has increased its 2026 revenue guidance to $950 million-$1.05 billion, with ambitious targets of $2 billion in Cushing’s sales and over $1 billion for Lifyorli by the end of the decade.